India, Feb. 28 -- Japan-headquartered pharmaceutical firm Eisai has entered into an exclusive license agreement with a subsidiary of SciClone Pharmaceuticals (Holdings) Limited (Shanghai, China) for the development and distribution of tasurgratinib succinate (E7090, Japan brand name: TASFYGO) in the Greater China region (Mainland China, Hong Kong, Macau, and Taiwan).

Eisai retains global rights outside these regions and will continue manufacturing and marketing in Japan, where tasurgratinib was launched in November 2024.

Under the agreement, Eisai will receive an upfront payment, milestone payments tied to development progress and regulatory approvals, as well as sales-based milestone payments and royalties upon commercialization.

Tasu...